DUX4 suppresses MHC Class I

See our multi-year grant co-funded by Friends and The Chris Carrino Foundation for FSHD.

The Fred Hutchinson Cancer Research Center press release below provides a brief overview of the findings, tying DUX4 with cancer research, an important element to attract pharmaceuticals to the FSHD arena, and one which Dr. Stephen Tapscott has been espousing for many years.


New Research Identifies Gene That Hides Cancer Cells from Immunotherapy

Findings in Developmental Cell show that expression of an early developmental gene prevents the immune system from identifying and attacking cancer cells

SEATTLE — July 18, 2019 — A team at Fred Hutchinson Cancer Research Center has identified a gene that could make immunotherapy treatments, specifically checkpoint inhibitors, work for a wider variety of cancer patients. The study, published today in Developmental Cell, found that when the DUX4 gene is expressed in cancer cells, it can prevent the cancer from being recognized and destroyed by the immune system.

The team, led by Drs. Robert Bradley and Stephen Tapscott, looked at the gene expression profiles of nearly 10,000 cancers from 33 different cancer types and discovered that DUX4, a gene mostly known for its link to a specific muscular dystrophy (facioscapulohumeral dystrophy, or FSHD), consistently presented itself in many different solid tumors, including cancers of the bladder, breast, lung, kidney and stomach. DUX4 prevented immune cells from recognizing the cancer cells, so that patients whose cancers expressed the gene were less likely to respond to immunotherapy. Because DUX4 is expressed in many cancers, blocking its activity might increase the success of immune checkpoint inhibitors.

“Immunotherapy can be incredibly powerful against previously untreatable cancers, but it isn’t effective yet for most patients,” said Bradley. “Understanding the mechanisms that prevent the immune system from identifying and attacking tumors is a first step toward finding cures for all cancer patients.”

Tapscott, who has previously studied the role of DUX4 in early development and in FSHD muscular dystrophy, notes the findings are an example of how the rapid, but regulated, growth in early development can be re-activated in cancers as rampant and unregulated cell growth. DUX4 is normally expressed in early development, when embryonic cells need to evade detection by the maternal immune system.

“This study suggests that cancer cells express DUX4 to hijack a normal early developmental program that can suppress anti-cancer immune activity,” said Tapscott.

Tapscott further notes there is no increased cancer risk in individuals with FSHD, which indicates the cancer cells are using DUX4 as a developmental tool to avoid the immune system, but not as a driver that causes cancer.

Bradley and Tapscott hope their work will eventually lead to the development of DUX4-targeted treatments that will enhance the success of immunotherapies for a broad range of cancers.

The National Institutes of Health (grant numbers: P01NS069539 and R01AR045203), Friends of FSH Research, Chris Carrino Foundation for FSHD, and Leukemia & Lymphoma Society funded this study. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Bradley, Tapscott, and co-authors Guo-Liang Chew and Amy Campbell are inventors on a provisional patent application submitted by Fred Hutch that covers DUX4 expression in cancers and response to immunotherapy.